Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
16 evidence topics · 11 sources
Guideline statements on suspicion, biomarker screening, and genetic confirmation
“Statement #9: The signs and symptoms of NPC are nonspecific, which may lead to misdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the presence of cataplexy and/or saccadic eye movement abnormalities should raise suspicion of NPC and help differentiate NPC from other neurodegenerative disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #12: Biomarker assessment should be considered the first‐line test to screen for NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three classes of biochemical markers are currently in use (oxysterols, PPCS, and lyso‐SM) or development (bile acid derivatives).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the diagnosis must be confirmed by deoxyribonucleic acid (DNA) sequencing, although diagnostic routes depend on tool availability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #13: Any individual whose diagnosis of NPC is considered based on their clinical manifestation and/or abnormal biomarker profile should undergo genetic testing for NPC genes to confirm the diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Referral to a clinical geneticist or genetic counselor should be considered following NPC diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biomarkers: oxysterols, PPCS and lyso-SM, and bile acids
“The oxysterols cholestane‐3β, 5α, 6β‐triol (C‐triol) and 7‐ketocholesterol (7‐KC) are sensitive markers of NPC, though C‐triol is more specific” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Striking elevations of PPCS have been reported in both NPC and ASMD, with high sensitivity for detecting both disorders but poor distinction between them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high PPCS/lyso‐SM ratio appears to be very specific to NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is highly sensitive and more specific than oxysterols (only elevated in ASMD and NPC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing: variant spectrum and limits of routine sequencing
“Genetic testing (NPC1 and NPC2) is recommended to confirm NPC diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, some genetic changes (e.g., deep intronic variants, complex structural variants) may not be identified by routine sequencing methods and require complementary testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The identification of two alleles with known disease‐causing variants in either the NPC1 or NPC2 gene confirms the diagnosis of NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To date, about 700 different NPC1 variants have been reported, among which around 420 are considered pathogenic, with only a limited number of common or recurrent (often in certain populations) variants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suspicion Index screening tools
“The Niemann‐Pick disease type C Suspicion Index (NPC‐SI) has been developed as a simple, interactive screening tool to assist HCPs in the early identification and referral of individuals suspected of NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC‐SI includes two age‐specific screening tools: one for individuals older than 4 years and another for individuals younger than four (early‐onset NPC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early-onset Suspicion Index for children aged 4 years or younger
“An early-onset NP-C SI was constructed following retrospective chart review of symptom presentation in 200 patients from nine centres comprised of 106 NP-C cases, 31 non-cases and 63 controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Visceral symptoms were amongst the strongest predictors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Except for gelastic cataplexy and vertical supranuclear gaze palsy, central nervous system symptoms were not discriminatory in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The early-onset NP-C SI can help physicians, especially those with limited knowledge of NP-C, to identify patients aged ≤4 years who warrant further investigation for NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical findings by age group and first-line laboratory tests
Molecular testing approaches
Neonatal cholestasis as a presentation of NPC
PPCS biomarker performance
“Blood‐based biomarkers have replaced filipin staining.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PPCS‐based assays now offer 100% sensitivity, 96.6% specificity in identifying NP‐C1 cases from controls and NP‐C1 carriers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay by age at neurological onset: NPC Registry
“A diagnostic delay was apparent in each of these age at neurological onset categories, with a mean delay between the appearance of first neurological symptoms and a confirmed diagnosis of NP-C of 2.5 years in early-infantile, 4.3 years in late-infantile, 6.2 years in juvenile, and 6.3 years in adolescent/adult patients (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay in pooled cohorts
Mean age at diagnosis: International Niemann-Pick Disease Registry
Diagnostic challenges and consequences
“Challenges also remain in differential diagnosis, prolonged times to diagnosis, and in some cases, misdiagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, NPC patients may encounter delayed or restricted access to suitable management strategies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor diagnostic program: Test for NPC and NPC GenomeComplete
Newborn screening: status and bile acid dried blood spot assay
“Newborn screening has the potential to enable earlier diagnosis prior to the onset of neurological symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NP‐C is not currently included in the Australian newborn screening programmes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high-throughput, mass spectrometry-based method was developed and validated to measure the glycine-conjugated bile acid in dried blood spots.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of dried blood spots from 4992 controls, 134 NPC carriers, and 44 NPC subjects provided 100% sensitivity and specificity in the study samples.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To address this critical question, we obtained the newborn DBS for already diagnosed NPC1 subjects (n=15) and carriers (n=3) residing in California, New York, and Michigan, states that archive residual DBS in biorepositories.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bile acid B, the more specific biomarker for which the fully validated DBS assay was developed, was detected in 8/15 NPC1 patients, and elevated above the cut-off in 2/15 patients (the two samples with the shortest storage time).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results demonstrate that newborn screening for NPC1 disease is feasible using bile acid biomarkers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote